$BPMC
Blueprint Medicines Corp Stock $bpmc

$bpmc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000155837023001465 Filed on February 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$63.29M	$38.78M	$204.0M
YoY Change	0.89%	-63.76%	13.3%
Cost Of Revenue	$3.175M	$4.848M	$17.81M
YoY Change	-37.49%	-35.78%	-0.67%
Gross Profit	$60.11M	$33.93M	$186.2M
YoY Change	4.27%	-65.89%	14.85%
Gross Profit Margin	94.98%	87.5%	91.27%
Selling, General & Admin	$70.95M	$64.02M	$237.4M
YoY Change	24.35%	18.12%	21.55%
% of Gross Profit	118.03%	188.67%	127.47%
Research & Development	$112.1M	$117.8M	$477.4M
YoY Change	8.67%	-66.98%	-20.57%
% of Gross Profit	186.44%	347.27%	256.37%
Depreciation & Amortization	$3.684M	$7.016M	$11.74M
YoY Change	126.29%	321.89%	81.12%
% of Gross Profit	6.13%	20.68%	6.3%
Operating Expenses	$183.0M	$183.7M	$714.8M
YoY Change	14.25%	-55.79%	-10.24%
Operating Profit	-$122.9M	-$149.8M	-$528.6M
YoY Change	19.87%	-52.62%	-16.65%
Interest Expense	-$5.819M	-$9.240M	-$16.77M
YoY Change	-1416.52%	-2095.68%	-802.72%
% of Operating Profit
Other Income/Expense, Net	-$4.833M	$1.429M	-$14.76M
YoY Change	43836.36%	-476.05%	-1745.82%
Pretax Income	-$129.0M	-$157.6M	-$552.3M
YoY Change	21.95%	-50.13%	-13.85%
Income Tax	$520.0K	$1.036M	$5.236M
% Of Pretax Income
Net Earnings	-$129.6M	-$158.6M	-$557.5M
YoY Change	22.23%	-50.22%	-13.44%
Net Earnings / Revenue	-204.72%	-409.08%	-273.24%
Basic Earnings Per Share	-$2.15		-$9.35
Diluted Earnings Per Share	-$2.15	-$2.65	-$9.35
COMMON SHARES
Basic Shares Outstanding	59.98M	59.83M	59.64M
Diluted Shares Outstanding	60.13M		59.64M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$822.2M	$945.0M	$945.0M
YoY Change	40.1%	98.06%	98.06%
Cash & Equivalents	$169.7M	$119.7M	$119.7M
Short-Term Investments	$652.4M	$825.3M	$825.3M
Other Short-Term Assets	$29.36M	$35.02M	$35.02M
YoY Change	-22.07%	93.89%	93.89%
Inventory	$17.52M	$29.70M	$29.70M
Prepaid Expenses
Receivables	$30.01M	$23.53M	$36.94M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$900.3M	$1.047B	$1.047B
YoY Change	31.01%	88.92%	88.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.74M	$33.34M	$115.2M
YoY Change	8.46%	8.61%	-4.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$139.2M	$133.5M	$133.5M
YoY Change	-54.6%	-76.06%	-76.06%
Other Assets	$34.47M	$21.59M	$54.57M
YoY Change	37.13%	47.49%	175.5%
Total Long-Term Assets	$320.0M	$303.3M	$303.3M
YoY Change	-29.83%	-56.57%	-56.57%
TOTAL ASSETS
Total Short-Term Assets	$900.3M	$1.047B	$1.047B
Total Long-Term Assets	$320.0M	$303.3M	$303.3M
Total Assets	$1.220B	$1.350B	$1.350B
YoY Change	6.74%	7.8%	7.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.56M	$2.729M	$2.729M
YoY Change	-41.19%	-67.25%	-67.25%
Accrued Expenses	$108.7M	$131.1M	$141.7M
YoY Change	7.98%	7.63%	9.07%
Deferred Revenue	$3.740M	$4.667M
YoY Change	-61.06%	-59.45%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.38M	$16.85M	$16.85M
YoY Change
Total Short-Term Liabilities	$172.7M	$183.2M	$183.2M
YoY Change	26.02%	22.35%	22.35%
LONG-TERM LIABILITIES
Long-Term Debt	$122.1M	$122.2M	$122.2M
YoY Change
Other Long-Term Liabilities	$3.102M	$10.30M	$529.8M
YoY Change	-69.39%	208.04%	302.17%
Total Long-Term Liabilities	$3.102M	$10.30M	$652.0M
YoY Change	-69.39%	208.04%	394.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$172.7M	$183.2M	$183.2M
Total Long-Term Liabilities	$3.102M	$10.30M	$652.0M
Total Liabilities	$806.1M	$835.2M	$835.2M
YoY Change	208.08%	196.72%	196.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.963B	-$1.833B
YoY Change	42.06%	43.71%
Common Stock	$60.00K	$60.00K
YoY Change	0.0%	1.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$414.3M	$514.7M	$514.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.220B	$1.350B	$1.350B
YoY Change	6.74%	7.8%	7.8%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$129.6M	-$158.6M	-$557.5M
YoY Change	22.23%	-50.22%	-13.44%
Depreciation, Depletion And Amortization	$3.684M	$7.016M	$11.74M
YoY Change	126.29%	321.89%	81.12%
Cash From Operating Activities	-$123.0M	-$121.4M	-$502.3M
YoY Change	-7.36%	760.17%	68.18%
INVESTING ACTIVITIES
Capital Expenditures	$2.584M	$1.481M	$8.919M
YoY Change	124.11%	-217.73%	188.73%
Acquisitions
YoY Change
Other Investing Activities	$175.4M	-$51.80M	$290.0K
YoY Change	-539.13%	-85.02%	-100.13%
Cash From Investing Activities	$172.8M	-$53.28M	-$149.5M
YoY Change	-520.52%	-84.64%	-33.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.491M	561.8M
YoY Change	-100.0%	-86.11%	1007.76%
NET CHANGE
Cash From Operating Activities	-123.0M	-121.4M	-502.3M
Cash From Investing Activities	172.8M	-53.28M	-149.5M
Cash From Financing Activities	0.000	2.491M	561.8M
Net Change In Cash	49.83M	-172.2M	-90.01M
YoY Change	-128.88%	-49.82%	-81.0%
FREE CASH FLOW
Cash From Operating Activities	-$123.0M	-$121.4M	-$502.3M
Capital Expenditures	$2.584M	$1.481M	$8.919M
Free Cash Flow	-$125.5M	-$122.9M	-$511.2M
YoY Change	-6.23%	855.86%	69.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001597264
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	bpmc	Debt Securities Available For Sale Credit Related Impairments Charges DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges	0
CY2021	bpmc	Debt Securities Available For Sale Credit Related Impairments Charges DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges	0
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember
CY2022	us-gaap	Defined Benefit Plan Sponsor Location Extensible List DefinedBenefitPlanSponsorLocationExtensibleList	http://xbrl.sec.gov/country/2022#CH
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37359
CY2022	dei	Entity Registrant Name EntityRegistrantName	BLUEPRINT MEDICINES CORPORATION
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3632015
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	45 Sidney Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	374-7580
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	BPMC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2022Q2	dei	Entity Public Float EntityPublicFloat	3003938145
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59983533
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119709000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	209948000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	825283000
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	267166000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23525000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25155000
CY2022Q4	bpmc	Unbilled Receivables Including Reimbursable Costs Current UnbilledReceivablesIncludingReimbursableCostsCurrent	13413000
CY2021Q4	bpmc	Unbilled Receivables Including Reimbursable Costs Current UnbilledReceivablesIncludingReimbursableCostsCurrent	11875000
CY2022Q4	us-gaap	Inventory Net InventoryNet	29697000
CY2021Q4	us-gaap	Inventory Net InventoryNet	21817000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	35024000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18064000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1046651000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	554025000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	133480000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	557529000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33344000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30700000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81854000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90162000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5195000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5171000
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	27789000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21589000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14638000
CY2022Q4	us-gaap	Assets Assets	1349902000
CY2021Q4	us-gaap	Assets Assets	1252225000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2729000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8333000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131123000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	121829000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10579000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8093000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4667000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11510000
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	17285000
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	16851000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	183234000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	149765000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92789000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	103315000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13624000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25066000
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	413045000
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	122232000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10301000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3344000
CY2022Q4	us-gaap	Liabilities Liabilities	835225000
CY2021Q4	us-gaap	Liabilities Liabilities	281490000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	666000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59958919
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59958919
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59141086
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59141086
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	60000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	59000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2358018000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2250250000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10443000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4133000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1832958000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1275441000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	514677000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	970735000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1349902000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1252225000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	204036000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	180080000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	793735000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17813000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17934000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	425000
CY2022	bpmc	Collaboration Profit Loss Sharing CollaborationProfitLossSharing	8948000
CY2021	bpmc	Collaboration Profit Loss Sharing CollaborationProfitLossSharing	7801000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	477419000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	601033000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	326860000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	237374000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	195293000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	157743000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	741554000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	822061000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	485028000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-16767000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2386000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6599000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2004000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1489000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-366000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14763000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	897000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6233000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-552281000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-641084000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	314940000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5236000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3001000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1058000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-557517000
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	4255000
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-2843000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7246000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3649000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	441000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-563827000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-643004000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	311202000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.76
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58518000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.35
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-644085000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	313882000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	270000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.01
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	475000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-278000
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.59
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59642000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54534000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59642000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58518000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56168000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	464359000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33283000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2154000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	76602000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2680000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	313882000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1470088000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	47303000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3313000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93035000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1081000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-644085000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	970735000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4611000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3524000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	99634000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6310000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-557517000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	514677000
CY2022	us-gaap	Profit Loss ProfitLoss	-557517000
CY2021	us-gaap	Profit Loss ProfitLoss	-644085000
CY2020	us-gaap	Profit Loss ProfitLoss	313882000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11735000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6479000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6559000
CY2022	bpmc	Lease Right Of Use Asset Amortization LeaseRightOfUseAssetAmortization	8364000
CY2021	bpmc	Lease Right Of Use Asset Amortization LeaseRightOfUseAssetAmortization	6306000
CY2020	bpmc	Lease Right Of Use Asset Amortization LeaseRightOfUseAssetAmortization	5791000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	98971000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	91630000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	75526000
CY2022	bpmc	Noncash Interest Expense NoncashInterestExpense	15799000
CY2022	bpmc	Noncash Customer Consideration NoncashCustomerConsideration	27500000
CY2021	bpmc	Acquired Productive Assets In Process Research And Development Expensed AcquiredProductiveAssetsInProcessResearchAndDevelopmentExpensed	259957000
CY2022	bpmc	Accretion Of Premiums And Discounts On Investments AccretionOfPremiumsAndDiscountsOnInvestments	-982000
CY2021	bpmc	Accretion Of Premiums And Discounts On Investments AccretionOfPremiumsAndDiscountsOnInvestments	1361000
CY2020	bpmc	Accretion Of Premiums And Discounts On Investments AccretionOfPremiumsAndDiscountsOnInvestments	466000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2622000
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3379000
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	429000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1572000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18143000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6387000
CY2022	bpmc	Increase Decrease In Customer Assets IncreaseDecreaseInCustomerAssets	3804000
CY2021	bpmc	Increase Decrease In Customer Assets IncreaseDecreaseInCustomerAssets	-6338000
CY2020	bpmc	Increase Decrease In Customer Assets IncreaseDecreaseInCustomerAssets	-4536000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8922000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12561000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4693000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6707000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16938000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-207000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12620000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	16320000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1786000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1440000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5816000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4221000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-791000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9368000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6095000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	16214000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4813000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4582000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4915000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8096000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7955000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6388000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-502277000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-298653000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	387035000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8919000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3089000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3159000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	258152000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	489705000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	655449000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	969437000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	349373000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	690830000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	538347000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	290000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-149541000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-225860000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-434249000
CY2022	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	415828000
CY2022	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	137786000
CY2020	bpmc	Proceeds From Issuance Of Common Stock Net Of Underwriting Discounts Commissions And Offering Expenses ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsCommissionsAndOfferingExpenses	503189000
CY2022	bpmc	Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan	8196000
CY2021	bpmc	Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan	50716000
CY2020	bpmc	Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan	35265000
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	79305000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	561810000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50716000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	617759000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90008000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-473797000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	570545000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215119000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689804000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119604000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-888000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-345000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124904000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215119000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689804000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9814000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	324000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	149000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	141000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6505000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	694000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	778000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119709000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	209948000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	684636000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5195000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5171000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5168000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124904000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215119000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689804000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Blueprint Medicines Corporation (the Company), a Delaware corporation incorporated on October 14, 2008, is a precision therapy company focused on genomically defined cancers and blood disorders. The Company’s approach is to leverage its novel research engine to systematically and reproducibly identify drivers of diseases in genomically defined patient populations, and to craft highly selective and potent drug candidates that are intended to provide significant and durable clinical responses to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has two approved precision therapies and is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. The Company is devoting substantially all of its efforts to research and development for current and future drug candidates and commercialization of AYVAKIT/AYVAKYT, GAVRETO and any current or future drug candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to those of other companies transitioning to a commercial stage, including but not limited to: successful commercialization of its current and future drugs, either by itself or through collaboration with third parties; establishing safety and efficacy in clinical trials and obtaining regulatory approvals for its drug candidates; competition from other companies; compliance with comprehensive and ongoing regulatory requirements and legislative changes; and the need to obtain adequate additional financing to fund the development of its drug candidates. If the Company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, eliminate or out-license certain of its research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of $1,078.5 million. Based on the Company’s current operating plans, the Company anticipates that its existing cash, cash equivalents and marketable securities will be sufficient to enable it to fund its current operations for at least the next twelve months from the issuance of the financial statements.</p>
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	1078500000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: revenue recognition, inventory, operating lease right-of-use assets, operating lease liabilities, stock-based compensation expense, accrued expenses, liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">related to the sale of future royalties and future revenues, equity investment, and income taxes. Actual results may differ from these estimates. The Russian invasion of Ukraine has not had a material impact on the Company’s business, results of operations and financial condition.</p>
CY2022Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	9788000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	18100000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	13500000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	9400000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and of Significant Suppliers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, investments, accounts receivable and unbilled account receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains its cash, cash equivalents and marketable securities in custodian accounts at high quality financial institutions, and as of December 31, 2022 and 2021, substantially all the Company’s cash, cash equivalents and marketable securities were invested in money market funds and U.S. government agency securities and treasury obligations, and consequently, the Company believes that such funds are subject to minimal credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivables and unbilled accounts receivables represent amounts arising from product sales and amounts due from the Company’s collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that its receivables are at risk of collection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The Company is dependent on third-party manufacturers to supply products for commercial and research and development activities associated with its drug and drug candidates, as applicable. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to the Company's drug and drug candidate activities. These activities, including the commercialization of AYVAKIT/AYVAKYT, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</p>
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q2	bpmc	Royalty Purchase Agreement Milestone Payments Achievement Of Specified Net Sales Milestones Maximum RoyaltyPurchaseAgreementMilestonePaymentsAchievementOfSpecifiedNetSalesMilestonesMaximum	165000000.0
CY2021Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	4345000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	968712000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9971000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	958763000
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	827383000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2709000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	824695000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	122
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	922300000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	122
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	56
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	550600000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	74
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	750500000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	825283000
CY2022Q4	bpmc	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One Positions Number DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOnePositionsNumber	104
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	267166000
CY2021Q4	bpmc	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One Positions Number DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOnePositionsNumber	29
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	133480000
CY2022Q4	bpmc	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Five Number DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveNumber	26
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	557529000
CY2021Q4	bpmc	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Five Number DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveNumber	56
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	958763000
CY2022Q4	bpmc	Debt Securities Available For Sale Positions Number DebtSecuritiesAvailableForSalePositionsNumber	130
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	824695000
CY2021Q4	bpmc	Debt Securities Available For Sale Positions Number DebtSecuritiesAvailableForSalePositionsNumber	85
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	349400000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	690800000
CY2021Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	4345000
CY2020Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1192000
CY2022	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	19292000
CY2021	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	8624000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	52.93
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.77
CY2022	bpmc	Contract With Customer Asset Allowance For Credit Loss Prior Period Increase Decrease ContractWithCustomerAssetAllowanceForCreditLossPriorPeriodIncreaseDecrease	-709000
CY2021	bpmc	Contract With Customer Asset Allowance For Credit Loss Prior Period Increase Decrease ContractWithCustomerAssetAllowanceForCreditLossPriorPeriodIncreaseDecrease	-396000
CY2022	us-gaap	Contract With Customer Asset Allowance For Credit Loss Recovery ContractWithCustomerAssetAllowanceForCreditLossRecovery	13140000
CY2022Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	9788000
CY2021	us-gaap	Contract With Customer Asset Allowance For Credit Loss Recovery ContractWithCustomerAssetAllowanceForCreditLossRecovery	5075000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1342
CY2021Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	4345000
CY2022Q4	bpmc	Inventory Current And Noncurrent Raw Materials Net Of Reserves InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves	4967000
CY2021Q4	bpmc	Inventory Current And Noncurrent Raw Materials Net Of Reserves InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves	10788000
CY2022Q4	bpmc	Inventory Current And Noncurrent Work In Process Net Of Reserves InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves	28427000
CY2021Q4	bpmc	Inventory Current And Noncurrent Work In Process Net Of Reserves InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves	17702000
CY2022Q4	bpmc	Inventory Current And Noncurrent Finished Goods Net Of Reserves InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves	2791000
CY2021Q4	bpmc	Inventory Current And Noncurrent Finished Goods Net Of Reserves InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves	3916000
CY2022Q4	bpmc	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	36185000
CY2021Q4	bpmc	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	32406000
CY2022Q4	us-gaap	Inventory Net InventoryNet	29697000
CY2021Q4	us-gaap	Inventory Net InventoryNet	21817000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	6488000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	10589000
CY2022Q4	bpmc	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	36185000
CY2021Q4	bpmc	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	32406000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2100000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	600000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5200000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	5200000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64626000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	56118000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31282000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25418000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33344000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30700000
CY2022	us-gaap	Depreciation Depreciation	6500000
CY2021	us-gaap	Depreciation Depreciation	6500000
CY2020	us-gaap	Depreciation Depreciation	6600000
CY2022Q4	bpmc	External Research Development And Commercial Contract Costs Current ExternalResearchDevelopmentAndCommercialContractCostsCurrent	66041000
CY2021Q4	bpmc	External Research Development And Commercial Contract Costs Current ExternalResearchDevelopmentAndCommercialContractCostsCurrent	68164000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	30744000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29166000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	17588000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	12611000
CY2022Q4	bpmc	Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	9046000
CY2021Q4	bpmc	Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	3926000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7704000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7962000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131123000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	121829000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11800000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	52300000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	43300000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	75000000.0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99000000.0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91600000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75500000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	99634000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	93035000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	76602000
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	663000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1405000
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1076000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	98971000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91630000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75526000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	98971000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91630000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75526000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	179700000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5682022
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	69.37
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	214675000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1192170
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	60.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	254933
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.10
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	385808
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	79.26
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6233451
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	69.14
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14833000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4187832
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	67.47
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M25D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	14833000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	32.30
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	80717
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	43167
CY2020	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	38516
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-557517000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-557517000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-644085000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-644085000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	313882000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	313882000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59642000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58518000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54534000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59642000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58518000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56168000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.76
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.35
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.01
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.59
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8182000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7296000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4512000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	bpmc	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Research And Development Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingResearchAndDevelopmentPercent	-0.0038
CY2021	bpmc	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Research And Development Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingResearchAndDevelopmentPercent	0.0007
CY2020	bpmc	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Research And Development Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingResearchAndDevelopmentPercent	-0.0047
CY2022	bpmc	Effective Income Tax Rate Reconciliation Domestic Tax On Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationDomesticTaxOnForeignEarningsPercent	0.0252
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0853
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0139
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0076
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0096
CY2022	bpmc	Effective Income Tax Rate Reconciliation Tax Credit General Business Percent EffectiveIncomeTaxRateReconciliationTaxCreditGeneralBusinessPercent	0.0042
CY2021	bpmc	Effective Income Tax Rate Reconciliation Tax Credit General Business Percent EffectiveIncomeTaxRateReconciliationTaxCreditGeneralBusinessPercent	-0.0402
CY2020	bpmc	Effective Income Tax Rate Reconciliation Tax Credit General Business Percent EffectiveIncomeTaxRateReconciliationTaxCreditGeneralBusinessPercent	0.1035
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0292
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0126
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0037
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0052
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0079
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0260
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.0003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.0039
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0095
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0047
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0064
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0150
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2776
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2008
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0035
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	193115000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	243670000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	140769000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	36874000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	36345000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23679000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	148572000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	150859000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	125153000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	48896000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	40617000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	32206000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4520000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6598000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7317000
CY2022Q4	bpmc	Deferred Tax Assets Royalty Purchase Agreements Milestones DeferredTaxAssetsRoyaltyPurchaseAgreementsMilestones	11507000
CY2022Q4	bpmc	Deferred Tax Assets Research And Development Capitalization DeferredTaxAssetsResearchAndDevelopmentCapitalization	84077000
CY2022Q4	bpmc	Deferred Tax Assets Financing Arrangement Transactions DeferredTaxAssetsFinancingArrangementTransactions	100155000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	23507000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	24798000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	19308000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1188000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	448000
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	29000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	652411000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	503364000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	348432000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5742000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5157000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5451000
CY2022Q4	bpmc	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	18599000
CY2021Q4	bpmc	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	20059000
CY2020Q4	bpmc	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	14539000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	1970000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	1003000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	1966000
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	625095000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	476180000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	328442000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	625100000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	476200000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	328400000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	148900000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	147700000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-42000000.0
CY2022Q4	bpmc	Operating Loss Carryforwards Limitations On Use Available For Utilization OperatingLossCarryforwardsLimitationsOnUseAvailableForUtilization	2000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	6575000
CY2021Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation	6482000
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	1200000
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	2000000.0
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	21830000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	18299000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	17600000
CY2022	us-gaap	Sublease Income SubleaseIncome	2132000
CY2021	us-gaap	Sublease Income SubleaseIncome	2174000
CY2020	us-gaap	Sublease Income SubleaseIncome	2919000
CY2022	us-gaap	Lease Cost LeaseCost	19698000
CY2021	us-gaap	Lease Cost LeaseCost	16125000
CY2020	us-gaap	Lease Cost LeaseCost	14681000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	15891000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	14896000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	14444000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	72000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28929000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	479000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17695000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18163000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18559000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	19089000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	19648000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	39264000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	132418000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29050000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	103368000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3700000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3000000.0
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1900000
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	5706000
CY2021Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets	4551000
CY2022Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	8763000
CY2021Q4	us-gaap	Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Projected Benefit Obligation DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation	7908000
CY2022Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-3057000
CY2021Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-3357000

Files In Submission

Name	View Source	Status
0001558370-23-001465-index-headers.html	Edgar Link	pending
0001558370-23-001465-index.html	Edgar Link	pending
0001558370-23-001465.txt	Edgar Link	pending
0001558370-23-001465-xbrl.zip	Edgar Link	pending
bpmc-20221231.xsd	Edgar Link	pending
bpmc-20221231x10k.htm	Edgar Link	pending
bpmc-20221231x10k006.jpg	Edgar Link	pending
bpmc-20221231x10k007.jpg	Edgar Link	pending
bpmc-20221231xex10d27.htm	Edgar Link	pending
bpmc-20221231xex10d39.htm	Edgar Link	pending
bpmc-20221231xex10d76.htm	Edgar Link	pending
bpmc-20221231xex10d77.htm	Edgar Link	pending
bpmc-20221231xex10d78.htm	Edgar Link	pending
bpmc-20221231xex10d79.htm	Edgar Link	pending
bpmc-20221231xex10d80.htm	Edgar Link	pending
bpmc-20221231xex10d81.htm	Edgar Link	pending
bpmc-20221231xex10d82.htm	Edgar Link	pending
bpmc-20221231xex10d83.htm	Edgar Link	pending
bpmc-20221231xex10d84.htm	Edgar Link	pending
bpmc-20221231xex10d85.htm	Edgar Link	pending
bpmc-20221231xex21d1.htm	Edgar Link	pending
bpmc-20221231xex23d1.htm	Edgar Link	pending
bpmc-20221231xex31d1.htm	Edgar Link	pending
bpmc-20221231xex31d2.htm	Edgar Link	pending
bpmc-20221231xex32d1.htm	Edgar Link	pending
bpmc-20221231xex5d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
bpmc-20221231_cal.xml	Edgar Link	unprocessable
bpmc-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bpmc-20221231x10k_htm.xml	Edgar Link	completed
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bpmc-20221231_lab.xml	Edgar Link	unprocessable
bpmc-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BPMC
Blueprint Medicines Corp Stock $bpmc

2023 Q1 Form 10-K Financial Statement

#000155837023001465 Filed on February 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPMC Blueprint Medicines Corp Stock $bpmc

2023 Q1 Form 10-K Financial Statement

#000155837023001465 Filed on February 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPMC
Blueprint Medicines Corp Stock $bpmc